INTRODUCTION
The immunomodulating pro-drugs azathioprine (AZA) and mercaptopurine (MP) are commonly used in the treatment of inflammatory bowel disease (IBD), as these conventional thiopurines are recommended in most IBD-guidelines as first line immunosuppressive maintenance treatment. Nevertheless, in daily practice up to half of IBD patients discontinue this therapy within 2 years. Treatment withdrawal is mostly due to the development of adverse drug reactions or therapy resistance, allegedly related to an aberrant metabolism, which seems theoretically disadvantageous 1,2 .
Several enzymes, of which the activities are partly pharmacogenetically determined, are crucial in the complex metabolism of thiopurines 3 . Among these enzymes are: hypoxanthineguanine phosphoribosyl transferase (HGPRT), xanthine oxidase (XO) and thiopurine S-methyl transferase (TPMT). Following conversion of AZA into MP, the first step in metabolism of MP to the pharmacologically active 6-thioguanine nucleotides (6-TGN) is driven by HGPRT. However, MP can also be oxidized by xanthine oxidase (XO) into inactive 6-thiouric acid (6-TUA) or methylated by thiopurine S-methyl transferase (TPMT) either directly into 6-methyl mercaptopurine or as a nucleotide into 6-methyl mercaptopurine ribonucleotides. These methylated products together have been named 6-MMPR (figure 1) 4 .
(HGPRT) and yields 6-thioinosine monophosphate (6-TIMP). However, MP can also be oxidized by xanthine oxidase (XO) into inactive 6-thiouric acid (6TUA), or methylated by thiopurine S-methyl transferase (TPMT) into 6-methyl mercaptopurine (6MMP). Moreover, MP can be inactivated by aldehyde oxidase (AOX), into 2-hydroxy-6-mercaptopurine (2OHMP). 6-Thioinosine monophosphate (6TIMP) can further be metabolized in three different ways. First, 6TIMP is a substrate for TPMT, which results in the formation of Figure 1 . Scheme of the thiopurine metabolism. Following conversion of azathioprine (AZA) into mercaptopurine (MP), the first step in bioactivation of MP is mediated by hypoxanthine-guanine phosphoribosyl transferase 6-methyl mercaptopurine ribonucleotides (6MMPR). These 6MMPR include 6-methyl thioinosine monophosphate (6-meTIMP), 6-methyl thioinosine diphosphate (6meTIDP) and 6-methyl thioinosine triphosphate (6meTITP). Second, 6TIMP can be phosphorylated via 6-thioinosine diphosphate (6TIDP) to 6-thioinosine triphosphate (6TITP), which in turn can be converted back to 6TIMP by inosine triphosphate pyrophosphohydrolase (ITPase). Third, inosine-5-monophosphate dehydrogenase (IMPDH) converts 6TIMP into 6-thioxanthosine monophosphate (6TXMP). 6-Thioxanthosine monophosphate (6TXMP), then, is converted by guanosine monophosphate synthetase (GMPS) into 6-thioguanine monophosphate (6TGMP), which in turn is phosphorylated by kinases to 6-thioguanine diphosphate (6TGDP) and 6-thioguanine triphosphate (6TGTP). Together these nucleotides form 6-TGN.
Patients with a skewed metabolism produce high red blood cell (RBC) 6-MMPR concentrations at the cost of 6-TGN formation. High 6-MMPR concentrations are associated with toxicity, in particular hepatotoxicity but even with myelotoxicity, whereas 6-TGN concentrations above a certain cut-off (>235 mmol/8*10^8 RBC) are associated with therapeutic efficacy [5] [6] [7] [8] . However, prospective studies have not be able to demonstrate that 6-TGN-guided dosing is superior to standard weight-based dosing, partly due to lack of proper pharmacodynamic tests 3, 9, 10 . The classical XO inhibitor allopurinol, usually prescribed for the treatment of gout, can enhance the efficacy of thiopurine therapy in renal transplant and IBD patients [11] [12] [13] [14] [15] [16] . The enhanced efficacy is assumed to be due to an increase of 6-TGN concentrations. As severe leukopenia may occur with high 6-TGN concentrations, thiopurine dosages need to be reduced to approximately 25% of their original weight-based dose during combination therapy. Sparrow and colleagues not only showed that upon allopurinol combination therapy 6-TGN concentrations increase, but also that 6-MMPR concentrations decrease 12 . Moreover, 6-MMPR associated liver test abnormalities ameliorated during combination therapy. Recently, combination therapy of allopurinol and low-dose thiopurine in IBD patients was also shown to prevent nonhepatic adverse events that had occurred during standard dosed thiopurine monotherapy 17 . Moreover, long-term treatment with this combination is effective and well-tolerated in IBD patients 16, 18 . The pharmacokinetic explanation of the substantial increase in 6-TGN and decrease in 6-MMPR concentrations upon combination therapy is not completely clarified, but may be explained by alterations in the activities of XO, TPMT and HGPRT. The aim of the present study was to observe possible effects of allopurinol and low-dose thiopurine combination therapy on XO, TPMT and HGPRT activities in IBD patients who previously failed thiopurine monotherapy, due to a skewed thiopurine metabolism.
MATERIALS AND METHODS

Study design
From April 2010 through January 2011, we performed a single centre uncontrolled prospective study at the Gastroenterology and Hepatology department of the VU University Medical Center in Amsterdam, The Netherlands. The study was carried out in accordance with the 2008 declaration of Helsinki. All patients were treated with 100 mg allopurinol 90 once daily in addition to low-dosed (25-33% of normal weight-based dose) AZA or MP. Patients were monitored for 12 weeks.
Population
In this single centre study, all consecutive IBD patients between 18 and 70 years of age who discontinued AZA or MP therapy and displayed a skewed thiopurine metabolism were eligible for this study. Thiopurines were discontinued due to either adverse reactions (including liver test abnormalities), or therapy resistance. Patients were consecutively recruited at the Outpatient Clinic. Therapy resistance was defined as on-going disease activity despite adequate dose escalation or steroid dependency for more than 6 months. All patients had a skewed thiopurine metabolism, arbitrarily defined as a 6-MMPR/6-TGN ratio above 20 during normal, bodyweight-based dosed conventional thiopurine therapy (1.0-1.5 mg/kg for MP and 2.0-2.5 mg/kg for AZA). Diagnosis of IBD was ascertained by standard clinical, radiological, histological and endoscopic criteria 19 . Thiopurines were prescribed according to a step-up approach as recommended in current IBD guidelines 20 .
Patient characteristics
The following patient characteristics were collected: gender, body mass index (BMI), type of IBD (Crohn's disease (CD) or ulcerative colitis (UC), including Montreal classification), smoking history, age and duration of IBD. As small bowel surgery may interfere with absorption of thiopurine therapy, data regarding previous intestinal surgery was documented. Treatment characteristics included type of thiopurine, dosage during monotherapy and combination therapy, concomitant medications and reason for initiating combination therapy. In addition, adverse reactions during combination therapy were documented. 
Evaluation of haematological and liver toxicity
Thiopurine metabolites
During thiopurine monotherapy, immediately prior to and at week 4 and 12 of combination therapy, 6-TGN and 6-MMPR concentrations were measured in RBC by a high performance liquid chromatography (HPLC) assay according to a slightly modified version of the previously described method of Dervieux and Boulieu 21, 22 . Measured 6-TGN concentrations by this Dervieux method were divided by 2.6 to make them comparable with those that would have been observed if using the method of Lennard and Singleton 23, 24 .
Enzyme assays
Activities of HGPRT, TPMT and XO were determined during thiopurine monotherapy, prior to and at week 4 and 12 of combination therapy. Blood samples were immediately handled and stored at -20 degrees Celsius after isolation of RBC and plasma. All enzyme activities were measured in a 37 degrees Celsius shaking water bath, at saturating substrate concentration and hence reflect a Vmax. The protein concentrations were measured with the Bradford assay. From this series, preliminary data of the activity of HGPRT after initiating allopurinol in a small group of IBD patients were previously reported 25 .
Hypoxanthine Guanine Phosphoribosyl Transferase (HGPRT)
The activity of HGPRT was measured in RBC and expressed in nmols of product per hour per mg protein (nmols/(h x mg protein). The RBC pellet was suspended in deionized water, sonicated and diluted in 250 mM Tris-HCL (pH 7.4) containing 25 mM MgCI 2. The HGPRT activity was measured in 20,000g diluted supernatant, as described earlier 26, 27 . Final substrate concentrations were 1.86 mM 5-phosporibosyl-1-pyrophosphate (PRPP) (SigmaAldrich Corp., St. Louis, MO, USA), with (18 -28 µg protein per assay) and 0.15 mM [8- 14 C] hypoxanthine (47 mCi/mmol, Moravek Biochemicals Inc., Brea, CA, USA).
Thiopurine S-Methyl Transferase (TPMT)
The activity of TPMT was measured in RBC in pmols per hour per mg protein. Thiopurine S-methyl transferase activity in RBC was determined by a validated high-performance liquid chromatography (HPLC) as described earlier 28 .
Xanthine oxidase (XO)
The activity of XO was measured in plasma by using the Amplex ® Red Xanthine/ Xanthine Oxidase Assay kit (Invitrogen, Carlsbad, CA, USA). Xanthine oxidase converts hypoxanthine in xanthine, and xanthine into uric acid, by both reactions, H 2 O 2 is released. With H 2 O 2 as cosubstrate, Horse radisch peroxidase oxidises Amplex Red to the detectable red-fluorescent oxidation product resorufin with absorption and fluorescence emission maxima of 571 and 585 nanometres, respectively. Plasma XO activity was expressed in mU per hour per ml, where 1 unit is defined as the amount of XO that will form 1 µmol of uric acid from xanthine.
Statistics
Continuous variables were expressed as median with interquartile range (IQR) and categorical variables were expressed as numbers and percentages. Correlations of quantitative variables were explored with the Spearman's rho test. To assess differences in enzyme activities over time the Friedman test was used. Post-hoc analysis with Wilcoxon Signed-Rank Tests was 92 conducted with a Bonferroni correction applied, resulting in a significance level set at p< 0.017. For all other variables p<0.05 was considered statistically significant. SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA) was used for statistical analysis.
RESULTS
Demographic characteristics
Fifteen patients, of whom twelve were females (80%), were included. Eleven patients (73%) were diagnosed with CD. The median age at initiating combination therapy was 40 years (IQR 29-57) and median duration of IBD was 1.5 year (IQR 0.8-12.0). Reasons to initiate combination therapy were hepatotoxicity, other adverse reactions, thiopurine resistance or a combination of hepatotoxicity and thiopurine resistance in 7 (47%), 4 (27%), 2 (13%) and 2 (13%) patients, respectively. The median duration of monotherapy with thiopurines was 5 months (IQR 2-33). During combination therapy thirteen patients were treated with 25 mg MP and two with 50 mg AZA daily. Four patients were concomitantly treated with 5-ASA, two of whom also used corticosteroids, and one patient only used corticosteroids alongside combination therapy. The 5-ASA dose was stable during the study follow-up. All patient characteristics are depicted in Table 1 .
The Montreal classification for Crohn's disease is based on three parameters: age of diagnosis (A), disease location (L) and disease behaviour (B). All parameters are subdivided; age in 1 below 16 year, 2 between 16 and 40 year and 3 above 40 year. Localisation in 1 ileal, 2 colonic, 3 ileocolic, 4 upper intestinal tract disease. Behaviour in 1 non-stricturing and non-penetrating, 2 stricturing, 3 penetrating, p perianal disease. For ulcerative colitis the Montreal classification parameters is extend of disease (E) and subdivided in 1, proctitis, 2 left-sided, 3 pancolitis. 
Enzyme assays
Thiopurine metabolites
At 4 weeks of combination therapy median (IQR) 6-TGN concentrations were increased in all patients, from 138 (119-188) to 235 (223-304) and to 265 pmol/8x10*8 (188-344) after 12 weeks of combination therapy (p<0.001). In contrast, both 6-MMPR concentrations and 6-MMPR/6-TGN ratios decreased in all patients (both p<0.001). Median (IQR) concentrations of 6-MMPR decreased dramatically from 13230 (7130-17420) to 690 (378-1325), and 540 (240-790) pmol/8x10*8, respectively. Similarly, the median (IQR) 6-MMPR/6-TGN ratio decreased from 96 (54-120) to 1.1 (0.7-2.0) and 1.9 (0.6-2.9) at 4 and 12 weeks of combination therapy, successively.
Evaluation of haematological and liver toxicity
All haematological and liver test variables are depicted in table 2. Leukocyte counts decreased from 7.5 x10*9/L (IQR 4.8-7.9) during thiopurine monotherapy to 4.4 x10*9/L (IQR 4.2-5.7) (p=0.037) at 12 weeks of combination therapy. Concentrations of ASAT, ALAT, and AP decreased and yGT slightly increased during combination therapy, although not statistically significant. Leukocytopenia (leukocyte count 0.9 x10*9/L) occurred in one patient, who unintentionally continued full-dose AZA during combination therapy. The leukocyte count of this patient recovered spontaneously 2 weeks after discontinuing combination therapy of AZA and allopurinol. Subsequently, adequate combination therapy was initiated and well tolerated without any signs of recurrent myelotoxicity. 
Tolerability of combination therapy
After a median duration of 4.5 weeks (IQR 1.8-8.0) three out of the initial fifteen patients (20%) failed combination therapy due to adverse reactions. Adverse reactions included nausea, fatigue and malaise. Two out of these three patients initiated combination therapy due to the same adverse reactions during thiopurine monotherapy. All adverse reactions were reversible upon cessation of combination therapy.
DISCUSSION
In this prospective pharmacological drug interaction study, we observed possible effects of allopurinol-thiopurine combination treatment on activities of key thiopurine metabolizing enzymes. In addition, we acknowledged the effect of allopurinol-thiopurine combination treatment on the formation of thiopurine metabolites in these IBD patients. A novel finding of this study is that upon allopurinol and low-dose thiopurine combination therapy HGPRT activity increased. Xanthine oxidase activity decreased, but TPMT activity seemed not affected despite a steep decrease in the methylated thiopurine metabolite concentrations during combination therapy. In agreement with previous studies, a marked increase in 6-TGN concentrations was observed during combination therapy 12, 29 .
The enhanced HGPRT activity upon combination therapy may be explained by a direct inductor effect of allopurinol or one of its metabolites, since thiopurine therapy itself seems to decrease HGPRT activity 30 . The enhanced HGPRT activity corroborates and extends preliminary data 25 . Ding and colleagues recently reported a correlation between the activity of HGPRT and 6-TGN concentrations, which was not observed in this study possibly due the small sample size 31 . Nonetheless, the enhanced HGPRT activity may at least in part explain the rise in 6-TGN concentrations as HGPRT is the first enzyme, responsible for the generation of 6-TGN. Since HGPRT is also involved in formation of methylated MP ribonucleotides, one would expect an increase in 6-MMPR. However, in line with previous studies these metabolites decreased dramatically and disappeared almost completely. In analogy with a previous study no difference in HGPRT activity was observed between gender and disease type (CD and UC) 31 .
As a classical XO inhibitor, allopurinol decreased the activity of XO after initiating allopurinol. With regard to thiopurine metabolism, decreased XO activity, either by inhibition or by a decreased activity of XO, causes less shunting towards the XO pathway, thereby increasing the concentration of MP that remains available for conversion into 6-TGN but theoretically also for the conversion into 6-MMPR (figure 1) 26, 32 . The latter is obviously not the case and the reason for this remains unsolved. The most logical explanation for the reduced 6-MMPR concentrations would be that allopurinol not only inhibits XO, but also TPMT, whether directly or indirectly by generation of an inhibiting metabolite.
Contrasting reports regarding TPMT inhibition by allopurinol have been published. Sparrow et al quoted unpublished work by Prometheus Laboratories that showed that RBC TPMT activity was not inhibited by allopurinol in vitro 12 . This finding has been disputed by others who argue that allopurinol is a prodrug that can only be converted to its active metabolite oxypurinol by XO and aldehyde oxidase (AOX), enzymes which are effectively absent in RBC. Oxypurinol is further converted to oxypurinol riboside monophosphate, which as a TPMT substrate may be responsible for (competitive) TPMT inhibition and the subsequent decrease in 6-MMPR production 33 . In addition, there is evidence that 2-hydroxy-6-mercaptopurine (2OHMP) is a TPMT inhibitor 34 . Also, 2OHMP can be formed from MP by AOX, especially when XO is inhibited ( figure 1) . Adding 2OHMP to a mixture of RBC and MP resulted in a significant reduction in RBC 6-MMPR production as compared to the mixture without 2OHMP 35 .
In line with two unpublished studies cited by Sparrow et al. our in vivo study did not show any alteration in TPMT activity upon allopurinol-thiopurine co-treatment 29 . Yet, 6-MMPR concentration decreased substantially. However, the TPMT assay reflects the capacity of RBC to methylate thiopurines. Any inhibition by potential inhibitors may not be found, since they may not accumulate in RBC or if so, they may be diluted to below level of detection when preparing RBC for the TPMT assay. Another potential alternative explanation for the decrease in 6-MMPR is that the reduced thiopurine dosage results in suboptimal concentrations for TPMT to function 36, 37 .
Although we observed a marked effect of allopurinol in 6-TGN formation, it is not clear whether the combination is optimal and if a similar effect would be observed at lower doses of allopurinol. Study of other XO-inhibitors might therefore be of great interest.
Besides HGPRT, inosine-5-monophosphate dehydrogenase (IMPDH) is also a rate limiting enzyme in the formation of the pharmacologically active 6-TGN. Previous studies, showed that patients with a high 6-MMPR/6-TGN ratio (above 20) had lower activity of IMPDH, compared to patients with a 6-MMPR/6-TGN below 20 38, 39 . Enhancement of IMPDH activity could thus increase 6-TGN concentrations. In addition, enhancement of the activity of guanosine monophosphate synthase (GPMS) may also provide an explanation for the increased 6-TGN concentration. As both enzymes contribute to 6-TGN production but not 6-MMPR, a decreased 6-MMP/6-TGN ratio would be expected upon their induction. This needs further confirmation.
Another enzyme involved in thiopurine metabolism possibly related with a skewed thiopurine metabolism is inosine triphosphate pyrophosphohydrolase (ITPase). A single nucleotide polymorphism has been reported in association with a decreased ITPase activity 40 . Genetic alterations in the ITPase gene, and thus a decreased ITPase activity, are associated with adverse outcomes of conventional thiopurine therapy, probably by the accumulation of 6-thioinosine-triphosphate (6-TITP) 41, 42 . Since 6-TITP is a substrate for TPMT, accumulation of 6-TITP may result in accumulation of 6-MMPR. Hence, ITPase deficiency might for a part be responsible for a skewed thiopurine metabolism. Whether ITPase induction contributes to high 6-TGN and low 6-MMPR concentrations observed during combination therapy remains to be established.
The ratio of 6-MMPR/6-TGN above 20 is arbitrarily defined but in line with other studies, however there is no widely accepted definition of a skewed thiopurine metabolism. The lowest 6-MMPR concentration in our study was 6220 pmol/8x10*8, suggesting that all our included patients displayed an aberrant thiopurine metabolism.
Although all patients were strictly informed to decrease the thiopurine dose when initiating allopurinol, one patient still continued the full weight-based dose and had to discontinue therapy temporarily due to leukocytopenia (leukocyte count 0.9 x10*9/L). This case underlines the serious risks of combination therapy underlining that all patients should be closely monitored.
In conclusion, HGPRT induction and XO inhibition seem to contribute to the notable increase of 6-TGN concentrations that occurs during allopurinol and low-dose thiopurine combination therapy. The activity of TPMT appears to be unaffected, at least in this study design, and thus the impressive decrease of 6-MMPR concentrations can not be attributed to a TPMT decrease. Yet, we cannot accurately predict individual responses to this combination therapy, hence stringent safety monitoring remains mandatory.
